CPT-Pharmacometrics & Systems Pharmacology

Papers
(The H4-Index of CPT-Pharmacometrics & Systems Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Issue Information46
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population43
Issue Information43
Evaluation of covariate effects in item response theory models36
Pharmacometric and statistical considerations for dose optimization32
Issue Information30
Issue Information29
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension29
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients28
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐127
Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations27
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach26
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential25
Enhance Multistate Models With Clinically Meaningful Graphs24
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation24
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates24
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease24
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist23
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story23
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy22
Issue Information22
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children22
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach22
0.036655902862549